PMP22抗体—艾普蒂 新品

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-7: Human cerebrum tissue, A172 cell, Mouse lung tissue, 293T cell, 231 cell, Mouse liver tissue, Mouse brain tissue lysates, Primary antibody: P06237(PMP22 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P06237(PMP22 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

**Background of PMP22 Antibodies**

The Peripheral Myelin Protein 22 (PMP22) is a glycoprotein critical for the formation and maintenance of myelin sheaths in peripheral nerves. It constitutes ~2–5% of total myelin protein and plays a role in Schwann cell differentiation, myelination, and nerve regeneration. Dysregulation of PMP22 is linked to hereditary neuropathies, notably Charcot-Marie-Tooth disease type 1A (CMT1A) caused by PMP22 duplication, and Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) due to PMP22 deletions.

PMP22 antibodies are autoantibodies targeting this protein, often investigated in autoimmune neuropathies. While PMP22 itself is not a common autoantigen, aberrant immune responses against it have been implicated in rare cases of chronic inflammatory demyelinating polyneuropathy (CIDP) or Guillain-Barré syndrome (GBS). Research suggests these antibodies may disrupt myelin integrity, impair nerve conduction, or interfere with Schwann cell function.

Detection of PMP22 antibodies (via ELISA, Western blot, or cell-based assays) remains experimental, with limited clinical utility compared to established biomarkers like anti-ganglioside antibodies. However, their study provides insights into autoimmune mechanisms in neuropathies and potential therapeutic targets. Current research focuses on clarifying their pathogenic role and diagnostic relevance, particularly in atypical inflammatory neuropathies unresponsive to standard therapies.